香港联交所最新资料显示，1月19日，高山企业(00616)股东将股票存入富途证券国际香港，存仓市3375 万港元，占比6.42%。 高山企业公布，2026年1月16日，该公司拟透过配售代理向不少于六名承配人配售最多1.1588亿股配售 股份，每股配售股份0.32港元，较当日收市价0.30港元溢价约6.67%。最高净筹约3671.08万港元，拟用 于根据集团现有银行贷款的再融资修订条款以偿还银行贷款。 ...

Group 1 - The company, CIMC Enric, announced a placement of up to 79.7 million new shares at a price of HKD 9.79 per share [1] - The placement price represents a discount of approximately 7.73% compared to the closing price of HKD 10.61 on Monday [1] - The proceeds from the placement are expected to be around HKD 780 million, with approximately 50% allocated for capital expenditures in the clean energy business and the remaining 50% for general business operations [1]

Core Viewpoint - CIMC Enric (03899.HK) announced a placement agreement with CITIC Securities to issue up to 79.7 million new shares at a price of HKD 9.79 per share, aiming to raise approximately HKD 780 million in total proceeds [1] Group 1: Placement Details - The company will issue and allocate a maximum of 79.7 million new shares under the general authorization [1] - The placement shares represent approximately 3.92% of the company's issued share capital as of the announcement date, and about 3.77% of the enlarged issued share capital post-placement [1] Group 2: Financial Implications - The estimated total proceeds from the placement are approximately HKD 780 million, with a net amount of about HKD 774 million expected [1] - The net proceeds will be allocated as follows: approximately 50% for capital expenditures in the clean energy business and approximately 50% for general business operations [1]

Core Viewpoint - Yufengchang Holdings (08631) announced a placement agreement to issue up to 8 million shares at HKD 0.39 per share, aiming to raise approximately HKD 2.8 million for settling unpaid fees and general working capital [1] Group 1 - The company plans to place shares through a placement agent to no fewer than six subscribers [1] - The maximum net proceeds from the placement are estimated to be around HKD 2.8 million [1] - The funds raised will be used to settle outstanding fees to professional service providers and other unpaid expenses, as well as for general operational purposes [1]

Core Viewpoint - Fuji High Industrial (00927) announced a placement agreement with a placement agent to issue up to 85.166 million new shares at a price of HKD 0.54 per share, representing a discount of approximately 15.63% from the closing price of HKD 0.64 on the date of the agreement [1] Group 1: Placement Details - The placement will be made to no fewer than six subscribers [1] - The maximum number of placement shares represents about 20.00% of the existing issued share capital as of the announcement date [1] - After the full issuance of the placement shares, the enlarged issued share capital will be approximately 16.67%, assuming no changes in the issued share capital from the announcement date to the closing date [1] Group 2: Use of Proceeds - The estimated net proceeds of approximately HKD 44.19 million will be allocated as follows: - About 45% for the existing operations and potential expansion of the company's headphone and audio business, including the purchase of machinery and equipment, as well as renovation and expansion of the company's factory in Indonesia [1] - Approximately 35% for the existing operations and potential expansion of the company's accessories and parts business, including the purchase of machinery and equipment and factory renovations [1] - The remaining 20% will be used for the company's working capital, including employee expenses, rent payments, general administrative expenses, and legal and professional fees [1]

115,880,000股最高配售股份数目相当于占公司于本公布日期已发行股本约6.62%；每股配售股份的配售 价为0.32港元，较每股股份于2026年1月16日(即配售协议日期)在联交所所报的收市价0.30港元溢价约 6.67%；在完成的前提下，预期配售事项的最高所得款项总额及(扣除配售佣金及其他配售事项的相关成 本及开支后)最高所得款项净额分别约为37,081,600港元及36,710,784港元。按此计算，每股配售股份的 净发行价将约为0.3168港元。预期配售事项的所得款项净额将用于根据集团现有银行贷款再融资修订条 款以偿还银行贷款。 格隆汇1月16日丨高山企业(00616.HK)公告，配售代理已有条件同意按尽力基准按每股配售股份0.32港 元的配售价向不少于六名承配人配售最多115,880,000股配售股份。倘承配人少于六名，公司将于有关配 售事项的进一步公布内披露该等承配人的姓名╱名称。 ...

格隆汇1月15日丨康龙化成(03759.HK)发布公告，2026年1月14日，公司与配售代理(即高盛与汇丰)订立 配售协议，据此，各配售代理各自同意(而非共同，亦非共同及个别)出任公司代理，并尽力促使承配人 按配售协议所载的条款及条件，以每股配售股份的配售价格认购总计5844.08万股新H股。 配售所得款项净额预期约为13.19亿港元，并将按以下方式动用：约70%将用于公司的项目建设，以加 强本公司实验室服务设施、药物工艺开发及生产设施的能力及产能；约10%将用于偿还银行贷款及其他 借款，以优化公司的资本结构；及约20%将用于补充营运资金及作其他一般公司用途。上述募集资金用 途届时会根据最终的发行规模进行相应调整。 配售股份数目分别占截至本公告日期现有已发行H股总数及现有已发行股份总数约19.86%和3.30%。配 售价每股配售股份港币22.82元，较1月14日(即配售协议签署的最后交易日)香港联交所所报收市价每股 H股港币24.94元折价约8.50%。配售股份将根据一般发行授权发行。 ...

Group 1 - The company, Litian Film Industry (09958), plans to place up to 72 million shares at a price of HKD 0.20 per share, targeting at least six subscribers [1] - If all placement shares are fully subscribed, the net proceeds are expected to be approximately HKD 14 million, which will be used for the company's general working capital [1]

Core Viewpoint - The company,药捷安康-B (02617.HK), has announced a placement agreement with CITIC Securities to issue 2.1 million shares at a price of HKD 92.85 per share, representing a discount of approximately 17.98% from the closing price of HKD 113.20 on January 13 [1] Group 1 - The placement shares represent about 0.70% of the existing issued H shares and 0.53% of the total issued shares as of the announcement date [1] - The expected total gross proceeds from the placement are approximately HKD 194.99 million, with net proceeds estimated at around HKD 190.14 million [1] Group 2 - The company plans to allocate approximately 60% of the net proceeds to fund clinical trials for its core product, Tinengotinib, in treating cholangiocarcinoma (CCA) and other indications [1] - About 30% of the net proceeds will be used for the development of other products, including TT-00973, TT-01488, and other molecules [1] - The remaining 10% of the net proceeds will be allocated for working capital and general corporate purposes [1]

格隆汇1月12日丨璋利国际(01693.HK)公告，于2026年1月12日，公司与配售代理订立配售协议，据此， 配售代理有条件同意按尽力基准促使以每股配售股份2.20港元的价格向目前预期的不少于六(6)名承配人 配售最多361万股配售股份。配售事项须待(其中包括)上市委员会批准配售股份上市及买卖後，方可作 实。配售价为每股配售股份2.20港元较最后交易日在联交所所报收市价每股2.25港元折让约2.22%。 假设配售股份获悉数配售，则配售事项的最高所得款项总额预期将为794万港元，及配售事项所得款项 净额(经扣除所有适用成本及开支，包括配售佣金及徵费)将约为769万港元，即每股配售股份之净价约 为2.13港元。公司拟将配售事项所得款项净额用作集团的一般营运资金(包括员工薪酬、专业费用及其 他营运开支)。 ...